Skip to main content
SpringerLink
Log in

Systemic Availability of Inhaled Budesonide and Fluticasone Propionate

Healthy versus Asthmatic Lungs

  • Review Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Inhaled corticosteroids are now recommended for the majority of patients with asthma. Although their therapeutic ratio is superior to that of oral corticosteroids, their long term use is associated with several potentially important adverse effects. A number of studies have compared the efficacy and/or systemic activity of the currently available inhaled corticosteroids, but the results of many of these studies have been conflicting. Although there are a number of factors that may explain these conflicting results, there is evidence that the type of individuals being studied is important. Extrapolation of the findings from healthy individuals to patients with asthma appears to be misleading because the systemic effects of some, but not all, inhaled corticosteroids are greater in healthy individuals than in patients with asthma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Notes

  1. Use of tradenames is for identification purposes only and does not imply endorsement.

References

  1. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl JMed 1999; 340: 1948–53

    Article  CAS  Google Scholar 

  2. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337: 8–14

    Article  PubMed  CAS  Google Scholar 

  3. Wong CA, Walsh LJ, Smith CJP, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000; 355: 1399–403

    Article  PubMed  CAS  Google Scholar 

  4. Meier CR, Schlienger RG, Kraenzlin ME, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283: 3205–10

    Article  PubMed  CAS  Google Scholar 

  5. Donnelly R, Williams KM, Baker AB, et al. Effects of budesonide and fluticasone on 24 hour plasma cortisol. Am J Respir Crit Care Med 1997; 156: 1746–51

    PubMed  CAS  Google Scholar 

  6. Fabbri L, Burge PS, Croonenborgh L, et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax 1993; 48: 817–23

    Article  PubMed  CAS  Google Scholar 

  7. Ayres JG, Bateman ED, Lundback B, et al. High dose fluticasone propionate, 1mg daily, versus fluticasone propionate, 2mg daily, or budesonide, 1.6mg daily, in patients with chronic severe asthma. Eur Respir J 1995; 8: 579–86

    PubMed  CAS  Google Scholar 

  8. Nielsen LP, Dahl R. Therapeutic ratio of inhaled corticosteroids in asthma. A dose range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function. Am J Respir Crit Care Med 2000; 162: 2053–7

    PubMed  CAS  Google Scholar 

  9. Derom E, Schoor JV, Verhaeghe W, et al. Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma. Am J Respir Crit Care Med 1999; 160: 157–61

    PubMed  CAS  Google Scholar 

  10. Daley-Yates PT, Tournant J, Kunka BL. Comparison of the systemic availability of fluticasone propionate in healthy subjects and patients with asthma. Clin Pharmacokinet 2000; 39(Suppl 1): 39–45

    Article  PubMed  CAS  Google Scholar 

  11. Weiner P, Berar-Yanay N, Davidovich A, et al. Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Chest 1999; 116: 931–4

    Article  PubMed  CAS  Google Scholar 

  12. Boorsma M, Andersson N, Larsson P, et al. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J 1996; 9: 1427–32

    Article  PubMed  CAS  Google Scholar 

  13. Clark DJ, Lipworth BJ. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax 1997; 52: 55–8

    Article  PubMed  CAS  Google Scholar 

  14. Grahnén A, Jansson B, Brundin RM, et al. A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler. J Clin Pharmacol 1997; 52: 261–7

    Google Scholar 

  15. Harrison TW, Wisniewski A, Honour J, et al. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler between healthy and asthmatic subjects. Thorax 2001; 56: 186–91

    Article  PubMed  CAS  Google Scholar 

  16. Brutsche MH, Brutsche IC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000; 356(9229): 556–61

    Article  PubMed  CAS  Google Scholar 

  17. Harrison TW, Tattersfield AE. Systemic bioavailability of fluticasone propionate and budesonide given by dry powder inhalers in healthy and asthmatic subjects [abstract]. Am J Respir Crit Care Med 2001; 163: A517

    Google Scholar 

  18. Lofdahl L, Thorsson L. Systemic availability of inhaled fluticasone propionate and budesonide was the same in asthmatic subjects and healthy subjects [abstract]. Am J Respir Crit Care Med 1999; 159: A118

    Google Scholar 

  19. Bisgaard H, Klug B, Sumby BS, et al. Fine particle mass from the Diskus inhaler and Turbuhaler in children with asthma. Eur Respir J 1998; 11: 1111–5

    Article  PubMed  CAS  Google Scholar 

  20. Melchor R, Biddiscombe MF, Mak VHF, et al. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 1993; 48: 506–11

    Article  PubMed  CAS  Google Scholar 

  21. Hogger P, Rawert L, Rohdewald P. Dissolution tissue binding and kinetics of receptor binding of inhaled glucocorticoids [abstract]. Eur Respir J 1993; 6: 584S

    Google Scholar 

Download references

Acknowledgements

Dr Harrison has attended and spoken at meetings at the request of AstraZeneca and Glaxo SmithKline pharmaceuticals.

Author information

Authors and Affiliations

  1. Respiratory Medicine Unit, Nottingham City Hospital, Nottingham, NG5 1PB, England

    Timothy Ward Harrison (Consultant Physician)

Authors
  1. Timothy Ward Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy Ward Harrison.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harrison, T.W. Systemic Availability of Inhaled Budesonide and Fluticasone Propionate. BioDrugs 15, 405–411 (2001). https://doi.org/10.2165/00063030-200115060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200115060-00006

Keywords

Search

Navigation